Double-Blinded Drug Discovery^® (DBD²)

Why DBD²?

The 99% failure rate in modern pharmaceutical R&D demands an overhaul of the present model; everyone agrees. Stakeholders (patients, taxpayers, and legislators) are losing patience - and life - waiting for applied research to deliver effective new medicines. Applying deeper knowledge of the chemical biology of drug action is the missing link crucial for translating bench-top discoveries into cures.

• LCGC's overarching mission is to improve translational research by connecting the exploratory excellence in academia with the chemical assets and development expertise in pharma to coalesce both their knowledge and know-how, harmonizing these disparate sectors with new synergy.

What Does DBD² Provide?

LCGC provides university 'drug hunters' the best diversity and target-focused 'snapshots' from the millions of compounds owned by pharmas, pre-formatted on HTS-ready plates. We help optimize the assay parameters for successful application of the orthogonal-pooled screening (OPS) approach, which is one of LCGC's core technologies. Support extends to a point when the most potent and selective drug leads are in hand. The new drug leads discovered become a compelling basis for further collaboration between the institution and pharmaceutical company. Ultimately, this will enable deeper investigation into mechanisms of drug action and propel candidates more successfully to the clinic.

How?

• Technology Transfer Offices in academia and Business Development professionals in pharmas review and approve a unified 'Library Access Agreement' under a CDA
• The PIs convey succinct (<1-page) target proposals via LCGC to Therapeutic Area Heads for approval
• Pharmaceutical company's chemical diversity is interrogated 500% more efficiently
• Target and institutional background IP are protected, as is pharma's chemical IP

Deliverables

• De-risk innovative targets and translate target 'druggability' faster using fewer resources
• Expand druggable space
• Explore drug synergy
• Accelerate technology licensing for commercialization
• Repurpose drug candidates
• Improved collaboration will help fulfill urgent unmet patient need

• Double-Blinded Drug Discovery^® Brochure

Image: Terra-cotta bas relief allegory of 'Industry and Invention' by Caspar Buberl
            Old Patent Office Great Hall, Washington, DC